Thursday, December 8, 2022, 7:15 PM – 9:15 PM Central Time (8:15 PM – 10:15 PM Eastern Time) – San Antonio, Texas

What Clinicians Want to Know: Addressing Current Questions and Controversies in the Management of ER-Positive Breast Cancer (Part 2 of a 2-Part Series)

A CME Satellite Symposium Held in Conjunction with the 2022 San Antonio Breast Cancer Symposium®

Location
San Antonio Marriott Rivercenter
101 Bowie St
San Antonio, TX 78205
Hotel Phone: (210) 223-1000

Program Schedule — Central Time
7:00 PM – 7:15 PM — Registration
7:15 PM – 9:15 PM — Dinner Meeting

Meeting Room
Grand Ballroom G-M (3rd floor)


This event will also be webcast live.
Please see Registration tab for details.
There is no registration fee for this event. For the in-person symposium in San Antonio, preregistration is required as seating is limited.  
 
Faculty
Aditya Bardia, MD, MPH
Director, Breast Cancer Research Program
Associate Professor
Harvard Medical School
Attending Physician
Massachusetts General Hospital
Boston, Massachusetts

Matthew P Goetz, MD
Erivan K Haub Family Professor of Cancer Research Honoring Richard F Emslander, MD
Professor of Oncology and Pharmacology
Enterprise Deputy Director, Translational Research
Director, Mayo Clinic Breast Cancer SPORE
Mayo Clinic
Rochester, Minnesota

Virginia Kaklamani, MD, DSc
Professor of Medicine
Ruth McLean Bowman Bowers Chair in Breast Cancer Research and Treatment
AB Alexander Distinguished Chair in Oncology
Associate Director for Clinical Research
Leader of the Breast Cancer Program
UT Health San Antonio
The University of Texas
MD Anderson Cancer Center
San Antonio, Texas


Kevin Kalinsky, MD, MS
Associate Professor
Department of Hematology and Medical Oncology
Emory University School of Medicine
Director, Glenn Family Breast Center
Director, Breast Medical Oncology
Winship Cancer Institute of Emory University
Atlanta, Georgia

Hope S Rugo, MD
Professor of Medicine
Director, Breast Oncology and Clinical Trials Education
University of California, San Francisco
Helen Diller Family Comprehensive Cancer Center
San Francisco, California

Moderator
Neil Love, MD
Research To Practice
Miami, Florida


This activity is supported by educational grants from AstraZeneca Pharmaceuticals LP, Daiichi Sankyo Inc, Exact Sciences Corporation, Lilly, Novartis, Sanofi, and TerSera Therapeutics LLC.
Program Schedule — Central Time
7:00 PM – 7:15 PM — Registration
7:15 PM – 9:15 PM — Dinner Meeting

MODULE 1: Current Role of Genomic Assays for Hormone Receptor (HR)-Positive Localized Breast Cancer — Dr Goetz

  • Clinicopathologic factors affecting the risk of recurrence and the decision to consult a genomic classifier for ER-positive localized breast cancer
  • Design, eligibility criteria and major findings from the Phase III RxPONDER trial evaluating the role of chemotherapy for patients with ER-positive, HER2-negative localized breast cancer with 1 to 3 positive lymph nodes and a 21-gene Recurrence Score® (RS) of ≤25
  • Long-term findings from the Phase III TAILORx study
  • Other recent studies informing the use of the 21-gene RS to guide neoadjuvant and adjuvant treatment decision-making
  • Available data sets with and current clinical utility of other genomic assays for ER-positive localized breast cancer

MODULE 2: Optimizing the Management of Localized ER-Positive Breast Cancer — Dr Kaklamani

  • Optimal selection and duration of adjuvant therapy for premenopausal and postmenopausal patients with ER-positive, HER2-negative localized breast cancer
  • Current clinical role of ovarian suppression as a means to preserve fertility during adjuvant chemotherapy
  • Biologic rationale for the evaluation of CDK4/6 inhibitors for ER-positive, HER2-negative localized breast cancer
  • Key efficacy and safety findings from the Phase III monarchE trial evaluating the addition of abemaciclib to standard adjuvant hormonal therapy for patients with ER-positive, HER2-negative breast cancer at high risk for recurrence
  • Guideline-endorsed indications for the use of adjuvant abemaciclib; identification of appropriate candidates for this strategy
  • Other ongoing studies (eg, NATALEE) evaluating CDK4/6 inhibitors as adjuvant or neoadjuvant therapy for ER-positive localized breast cancer
  • Findings with olaparib as adjuvant therapy among patients with ER-positive breast cancer with BRCA mutations in the Phase III OlympiA study; current role of adjuvant olaparib in this population

MODULE 3: Selection and Sequencing of Therapy for Patients with ER-Positive Metastatic Breast Cancer (mBC) — Dr Kalinsky

  • Long-term follow-up, including overall survival data, from pivotal clinical trials of palbociclib, ribociclib and abemaciclib for premenopausal and postmenopausal patients
  • Available data (eg, the MAINTAIN and PACE studies) evaluating the clinical utility of rechallenge with a CDK4/6 inhibitor for patients who have experienced disease progression on or after prior CDK4/6 inhibitor therapy; implications for later-line treatment
  • Mechanisms of resistance to CDK4/6 inhibition; prevalence, identification and prognostic significance of PIK3CA mutations in patients with ER-positive mBC
  • Available research findings with alpelisib-based treatment for patients with ER-positive mBC with a PIK3CA mutation, including those experiencing disease progression on a CDK4/6 inhibitor; optimal incorporation into current management algorithms
  • Spectrum, frequency and severity of alpelisib-related toxicities; optimal prevention and management strategies
  • Current role of PARP inhibitors for patients with HR-positive mBC with BRCA mutations

MODULE 4: Recent Appreciation of HER2 Low as a Unique Subset of HR-Positive Breast Cancer — Dr Bardia

  • Incidence and clinicopathologic characteristics of HER2-low breast cancer; appropriate testing strategies to identify patients with HER2-low disease
  • Historical management approach for HR-positive, HER2-low mBC; available data with established HER2-targeted agents (eg, trastuzumab, pertuzumab, T-DM1)
  • Mechanism of action of trastuzumab deruxtecan (T-DXd); rationale for its activity in patients with HER2-low breast cancer
  • Early-phase data with T-DXd for HER2-low mBC; effects of IHC status, HR status and prior therapy on outcomes
  • Key findings from the DESTINY-Breast04 trial evaluating T-DXd versus chemotherapy for patients with previously treated HER2-low advanced breast cancer
  • Recent FDA approval of T-DXd for previously treated HER2-low mBC; optimal sequencing for patients with HR-positive, HER2-low disease
  • Design, eligibility criteria and key endpoints of the Phase III DESTINY-Breast06 trial assessing T-DXd versus physicians’ choice of chemotherapy for HR-positive, HER2-low mBC progressing after CDK4/6 inhibitor therapy

MODULE 5: Novel Strategies Under Investigation for Patients with HR-Positive mBC — Dr Rugo

  • Available efficacy and safety data from the Phase III CAPItello-291 study of capivasertib and fulvestrant versus placebo and fulvestrant for recurrent HR-positive, HER2-negative mBC
  • Design, eligibility criteria and key efficacy and safety results from the Phase III EMERALD trial evaluating the oral selective estrogen receptor downregulator (SERD) elacestrant for patients with ER-positive mBC who had experienced disease progression on CDK4/6 inhibitor-based therapy
  • Available findings with the use of other oral SERDs (eg, camizestrant, imlunestrant, giredestrant, amcenestrant)
  • Biologic rationale for targeting TROP2 in HR-positive mBC; key outcomes from the Phase III TROPiCS-02 trial evaluating sacituzumab govitecan in this population
  • Mechanism of action of and available data with datopotamab deruxtecan for HR-positive, HER2-negative mBC

Target Audience
This activity is intended for medical oncologists, breast surgeons, nurses, radiation oncologists and other healthcare professionals involved in the diagnosis and treatment of breast cancer.

Learning Objectives
Upon completion of this activity, participants should be able to

  • Evaluate the results of genomic assays and other relevant patient- and treatment-related factors to personalize adjuvant systemic therapy for newly diagnosed ER-positive, HER2-negative, lymph node-negative or node-positive breast cancer.
  • Comprehend available findings with CDK4/6 inhibitors for localized ER-positive, HER2-negative breast cancer, and assess the current role of these agents as a component of adjuvant treatment.
  • Individualize the selection and sequence of systemic therapy for patients with ER-positive metastatic breast cancer (mBC), considering clinical presentation (eg, age, menopausal status, comorbidities, extent and sites of disease, biomarker status), prior treatment course and psychosocial status.
  • Appraise available research data with commercially available CDK4/6 inhibitors in the treatment of ER-positive mBC, and optimally incorporate these agents into patient care.
  • Recognize the frequency of phosphoinositide-3 kinase pathway mutations in patients with ER-positive mBC, and employ evidence-based approaches to targeting these alterations in individuals with ER-positive, HER2-negative, PIK3CA-mutated disease.
  • Appreciate published efficacy and safety data with PARP inhibitors for patients with localized or metastatic breast cancer harboring BRCA1/2 mutations, and consider the diagnostic and therapeutic implications for nonresearch care.
  • Recall the incidence, pathologic and molecular characteristics and clinical relevance of ER-positive, HER2-low mBC, and understand currently available and emerging management approaches for this disease subset.
  • Assess ongoing clinical studies evaluating novel agents and treatment strategies under development for ER-positive breast cancer, and counsel patients about the potential benefits of trial participation.

CME Credit Form
A CME credit link will be given to each participant at the conclusion of the activity.

Accreditation Statement
Research To Practice is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Credit Designation Statement
Research To Practice designates this live activity for a maximum of 2 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Content Validation and Disclosures
Research To Practice (RTP) is committed to providing its participants with high-quality, unbiased and state-of-the-art education and adheres to the ACCME’s Standards for Integrity and Independence in Accredited Continuing Education. Any individuals in a position to control the content of an accredited continuing education activity, including faculty, planners, reviewers and others, are required to disclose all relevant financial relationships with ineligible entities (commercial interests). All relevant conflicts of interest will have been mitigated prior to the commencement of this activity. In addition, all activity content is reviewed by RTP scientific staff and an external, independent physician reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations.

FACULTY — The following faculty reported relevant financial relationships with ineligible entities:

Dr Bardia — Consulting Agreements: AstraZeneca Pharmaceuticals LP, Daiichi Sankyo Inc, Foundation Medicine, Genentech, a member of the Roche Group, Gilead Sciences Inc, Lilly, Merck, Novartis, Pfizer Inc, Phillips HealthCare Services Ltd, Radius Health Inc, Sanofi; Contracted Research: AstraZeneca Pharmaceuticals LP, Daiichi Sankyo Inc, Genentech, a member of the Roche Group, Gilead Sciences Inc, Lilly, Merck, Novartis, Pfizer Inc, Radius Health Inc, Sanofi. Dr Goetz — Advisory Committee: ARC Therapeutics, Biotheranostics Inc, Blueprint Medicines, Sanofi; Consulting Agreements: AstraZeneca Pharmaceuticals LP, Biovica, Context Therapeutics, Eagle Pharmaceuticals, Lilly, Novartis, Pfizer Inc; Contracted Research: Lilly, Pfizer Inc, Sermonix Pharmaceuticals; Nonrelevant Financial Relationship (CME Presentation Fees): Clinical Education Alliance, Medscape, MJH Life Sciences; Nonrelevant Financial Relationship (Panelist): Total Health Conferencing. Dr Kaklamani — Advisory Committee and Consulting Agreements: AstraZeneca Pharmaceuticals LP, Athenex, Gilead Sciences Inc, Puma Biotechnology Inc; Contracted Research: Eisai Inc; Data and Safety Monitoring Board/Committee: Sanofi; Speakers Bureau: AstraZeneca Pharmaceuticals LP, Daiichi Sankyo Inc, Exact Sciences Corporation, Genentech, a member of the Roche Group, Gilead Sciences Inc, Novartis, Pfizer Inc, Seagen Inc. Dr Kalinsky — Advisory Committee: 4D Pharma PLC, AstraZeneca Pharmaceuticals LP, Daiichi Sankyo Inc, Gilead Sciences Inc, Lilly, Menarini Silicon Biosystems, Merck, Mersana Therapeutics Inc, Myovant Sciences, Novartis, OncoSec Medical, Pfizer Inc, Puma Biotechnology Inc, Seagen Inc, Takeda Pharmaceuticals USA Inc; Contracted Research: Ascentage Pharma, AstraZeneca Pharmaceuticals LP, Daiichi Sankyo Inc, Genentech, a member of the Roche Group, Lilly, Novartis; Data and Safety Monitoring Board/Committee: Merck. Dr Rugo — Consultancy/Advisory Support: Blueprint Medicines, Napo Pharmaceuticals Inc, Puma Biotechnology Inc; Contracted Research: Ambrx, Astellas, AstraZeneca Pharmaceuticals LP, Daiichi Sankyo Inc, Genentech, a member of the Roche Group, Gilead Sciences Inc, GlaxoSmithKline, Lilly, Merck, Novartis, OBI Pharma Inc, Pfizer Inc, Pionyr Immunotherapeutics, Seagen Inc, Sermonix Pharmaceuticals, Taiho Oncology Inc, Veru Inc; Travel Support to Academic Meetings: AstraZeneca Pharmaceuticals LP, Gilead Sciences Inc, Merck.

MODERATOR — Dr Love is president and CEO of Research To Practice. Research To Practice receives funds in the form of educational grants to develop CME activities from the following companies: AbbVie Inc, Adaptive Biotechnologies Corporation, ADC Therapeutics, Agios Pharmaceuticals Inc, Alexion Pharmaceuticals, Amgen Inc, Array BioPharma Inc, a subsidiary of Pfizer Inc, Astellas, AstraZeneca Pharmaceuticals LP, Aveo Pharmaceuticals, Bayer HealthCare Pharmaceuticals, BeiGene Ltd, BeyondSpring Pharmaceuticals Inc, Blueprint Medicines, Boehringer Ingelheim Pharmaceuticals Inc, Bristol-Myers Squibb Company, Celgene Corporation, Clovis Oncology, Coherus BioSciences, CTI BioPharma Corp, Daiichi Sankyo Inc, Eisai Inc, Elevation Oncology Inc, EMD Serono Inc, Epizyme Inc, Exact Sciences Corporation, Exelixis Inc, Five Prime Therapeutics Inc, Foundation Medicine, G1 Therapeutics Inc, Genentech, a member of the Roche Group, Genmab, Gilead Sciences Inc, GlaxoSmithKline, Grail Inc, Halozyme Inc, Helsinn Healthcare SA, ImmunoGen Inc, Incyte Corporation, Ipsen Biopharmaceuticals Inc, Janssen Biotech Inc, administered by Janssen Scientific Affairs LLC, Jazz Pharmaceuticals Inc, Karyopharm Therapeutics, Kite, A Gilead Company, Kronos Bio Inc, Lilly, Loxo Oncology Inc, a wholly owned subsidiary of Eli Lilly & Company, MEI Pharma Inc, Merck, Mersana Therapeutics Inc, Mirati Therapeutics Inc, Natera Inc, Novartis, Novartis Pharmaceuticals Corporation on behalf of Advanced Accelerator Applications, Novocure Inc, Oncopeptides, Pfizer Inc, Pharmacyclics LLC, an AbbVie Company, Puma Biotechnology Inc, Regeneron Pharmaceuticals Inc, Sanofi, Seagen Inc, Servier Pharmaceuticals LLC, SpringWorks Therapeutics Inc, Sumitomo Dainippon Pharma Oncology Inc, Taiho Oncology Inc, Takeda Pharmaceuticals USA Inc, TerSera Therapeutics LLC, Tesaro, A GSK Company, TG Therapeutics Inc, Turning Point Therapeutics Inc, Verastem Inc and Zymeworks Inc.

Research To Practice CME Planning Committee Members, Staff and Reviewers — Planners, scientific staff and independent reviewers for Research To Practice have no relevant conflicts of interest to disclose.

Supporters
This activity is supported by educational grants from AstraZeneca Pharmaceuticals LP, Daiichi Sankyo Inc, Exact Sciences Corporation, Lilly, Novartis, Sanofi, and TerSera Therapeutics LLC.

San Antonio Marriott Rivercenter
101 Bowie St
San Antonio, TX 78205
Hotel Phone: (210) 223-1000

Meeting Room
Grand Ballroom G-M (3rd floor)

Directions
The Marriott Rivercenter hotel is conveniently located within walking distance (1.5 blocks) of the Henry B González Convention Center, where the 2022 San Antonio Breast Cancer Symposium is taking place.

 
This activity is intended for medical oncologists, breast cancer surgeons, nurses, radiation oncologists and other healthcare professionals involved in the diagnosis and treatment of breast cancer.

​ ​
IN-PERSON registration for clinicians in practice/healthcare professionals
Thank you for your interest in our CME program. At this time online preregistration is closed for this in-person event. SEATS ARE STILL AVAILABLE FOR THE SESSION. Our onsite registration desk will be open at 6:45 PM CT on Thursday, December 8th. If you are interested in attending, please visit our registration desk outside the Grand Ballroom G-M (third floor) of the Marriott Rivercenter hotel (101 Bowie St), within walking distance of the Henry B Gonzalez Convention Center.

If you have any questions, please feel free to contact us via email at Meetings@ResearchToPractice.com, or call (800) 233-6153.

NOTICE:
Registration for this event is independent of registration for SABCS.

LIVE WEBCAST registration for all professionals

Please note, we will stream this event over Zoom. After registering you will receive a separate confirmation from Zoom with the viewing instructions.

REGISTRATION FOR WEBCAST »

Registration for groups
If you are registering a group (more than 1 person) for this event, please contact us at Meetings@ResearchToPractice.com or (800) 233-6153.
To ensure seating and meal service, please check in at our onsite registration desk 30 minutes before the start of the meeting. We cannot guarantee seating after the start of the program.

Photography and/or video recording may be taken during the educational program by Research To Practice and used in future educational offerings.

Research To Practice fully complies with the legal requirements of the ADA. If you are in need of assistance (ie, physical, dietary, et cetera), please contact us prior to the event at (800) 233-6153.

 

The content of this Open Satellite Event and opinions expressed by presenters are those of the sponsor or presenter and are not of the San Antonio Breast Cancer Symposium.